A Critical Analysis of Vitamin D and Calcium in Women during Pregnancy

Aim: To find out the frequency of vitamin D and calcium in pregnant women and their effects on fetus as well as mothers. Study Design: Retrospective study. Place and Duration of Study: Darul Shifa Clinic & Maternity Home Karachi Pakistan from 1st July 2020 to 31st December 2020. Methodology: One hundred and twenty patients with proper evidence of pregnancy were enrolled. All patients from age 18 years to age 35 years with no other disease were included and those women who have some other diseases or age outliers were excluded. Results: There is a significance difference in the vitamin D and calcium during the period of pregnancy. In the group A (18 years to 25 years) the significance difference of vitamin D was (P=0.000) while the calcium was (P=0.200). In the group B (26 years to 30 years) the significance difference of vitamin D was (P=0.000) while the Calcium was (P=0.071) and in the group C (30 years to 35 years) there was no significant change of vitamin D and calcium (P=0.000). The result of group C is different from the results of the above two groups, because in this age majority of the women were living in a congested houses as well as were spending a depressive life due to home problems, husband wife compromise problems, children problems, financial problems etc. and all such problems have a direct impact on their pregnancy Conclusion: It was statistically found that the Vitamin D and calcium values show significances changes during pregnancy in contrast to the normal women. Key words: Vitamin D, Calcium, Pregnant women

Download Full-text

A STUDY OF SERUM LEVELS OF 25 (OH)VITAMIN D AND CALCIUM IN PRE-ECLAMPSIA, ECLAMPSIA AND NORMAL HEALTHY PREGNANT WOMEN

10.36106/ijar/8500102 ◽

2021 ◽

pp. 1-5

Author(s):

Rama Garg ◽

Monika Monika ◽

Parneet Kaur ◽

Jasvir Singh

Keyword(s):

Vitamin D ◽

Pregnant Women ◽

Serum Levels ◽

Medical College ◽

Northern India ◽

Group A ◽

The Mean ◽

The Difference ◽

25 Oh Vitamin D ◽

Group B

BACKGROUND- It is important to know the modiable risk factors related to the occurrence of preeclampsia and eclampsia, which can help in its primary prevention. To study the serum levels of 25(OH)Vitamin-D and OBJECTIVESCalcium in pre-eclampsia, eclampsia, and normal healthy pregnant women. The prospective observational MATERIAL AND METHODS- study was conducted from 2018-2021 in the Department of Obstetrics and Gynecology, Government Medical College, Northern India. Eighty women were divided into 3 groups: Group A- women with preeclamp sia (30); Group B -women with eclampsia (30); Group C– normal healthy pregnant women (20). Investigations: 1. S.25(OH) VIT D level; 2. S. Calcium level. Results- The mean ± SD levels of vitamin D in women of Group A (preeclampsia) was 21.40 ± 7.11, in Group B (eclampsia) was 16.98 ± 6.62 and in Group C (normal healthy pregnant women) was 37.86 ± 11.34. This data is statistically signicant (P=0.016). The mean ± SD of levels of serum calcium in women of Group A (preeclampsia) was 8.68 ± 0.63, in Group B (eclampsia) was 7.86 ± 0.90 and in Group C (normal healthy pregnant women) was 9.07 ± 0.50. The difference between groups was statistically signicant (P=0.018). Both S. Vitamin D and S. Calc CONCLUSION- ium levels have a negative correlation with systolic and diastolic blood pressure. Women having decreased levels of S. Vitamin D and S. Calcium are more prone to develop hypertensive disorders of pregnancy

Download Full-text

Opposite correlation of 25-hydroxy-vitamin D- and 1,25-dihydroxy-vitamin D-metabolites with gestational age, bone- and lipid-biomarkers in pregnant women

Scientific Reports ◽

10.1038/s41598-021-81452-9 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Oleg Tsuprykov ◽

Saban Elitok ◽

Claudia Buse ◽

Chang Chu ◽

Bernhard Karl Krämer ◽

...

Keyword(s):

Vitamin D ◽

Alkaline Phosphatase ◽

Pregnant Women ◽

Clinical Chemistry ◽

Water Soluble ◽

Target Cells ◽

Vitamin D Metabolites ◽

Specific Alkaline Phosphatase ◽

Bone Specific Alkaline Phosphatase ◽

Group B

Abstract25-Hydroxyvitamin D (25OHD) and 1,25-dihydroxyvitamin D (1,25(OH)2D) need to be bound to carrier proteins to be transported to their target cells. The majority of either 25OHD or 1,25(OH)2D is bound to vitamin D-binding protein (DBP), a smaller fraction is bound to albumin and only very small amounts of 25OHD or 1,25(OH)2D are free. Albumin-bound 25OHD or 1,25(OH)2D is relatively easily available after dissociation from albumin. Thus, the sum of free and albumin-bound forms is called bioavailable 25OHD and bioavailable 1,25(OH)2D. Total 25OHD and 1,25(OH)2D are defined as the sum of free, albumin-bound and DBP-bound 25OHD and 1,25(OH)2D, respectively. This cross-sectional study in 427 pregnant women compared the correlation of the six vitamin D compounds with biomarkers of bone health, lipid metabolism, kidney function, endocrine parameters, and group B water-soluble vitamins. Among the 25OHD metabolites analysed, total 1,25(OH)2D showed clearly the best correlation with calcium, bone-specific alkaline phosphatase, adiponectin, LDL, HDL, urea, thyroxine, and group B water-soluble vitamins. When comparing the three 25OHD metabolites, both free 25OHD and bioavailable 25OHD showed overall good correlations with calcium, bone-specific alkaline phosphatase, adiponectin, LDL, HDL, urea, thyroxine, triiodothyronine, and group B water-soluble vitamins, The correlations of 1,25(OH)2D and 25OHD metabolites went always in opposite directions. Only PTH correlates always inversely with all six vitamin D compounds. In conclusion, free 25(OH)D and bioavailable 25(OH)D are more precise determinants of the vitamin D status than total 25(OH)D in normal pregnancy, whereas total 1,25(OH)2D is superior to free and bioavailable 1,25(OH)2D. Except for PTH, correlations of 25(OH)D and 1,25(OH)2D metabolites with typical clinical chemistry readouts go in opposite directions.

Download Full-text

Impact of the 25-Hydroxycholecalciferol Concentration and Vitamin D Deficiency Treatment on Changes in the Bone Level at the Implant Site during the Process of Osseointegration: A Prospective, Randomized, Controlled Clinical Trial

Journal of Clinical Medicine ◽

10.3390/jcm10030526 ◽

2021 ◽

Vol 10 (3) ◽

pp. 526

Author(s):

Jakub Kwiatek ◽

Aleksandra Jaroń ◽

Grzegorz Trybek

Keyword(s):

Vitamin D ◽

Vitamin D Deficiency ◽

Controlled Clinical Trial ◽

Randomized Controlled ◽

Group A ◽

Bone Level ◽

Group B ◽

Implant Treatment ◽

Correct Level ◽

25 Hydroxycholecalciferol

Introduction: The most important factor which is responsible for the positive course of implant treatment is the process of osseointegration between the implant structure and the host’s bone tissue. The aim of this study was to assess what effect the 25-hydroxycholecalciferol concentration and vitamin D deficiency treatment have on changes in the bone level at the implant site during the process of osseointegration in the mandible. Materials and Methods: The study was with 122 people qualified for implant surgery, who were assigned to three research groups (A, B, and C). Laboratory, clinical, and radiological tests were performed on the day of surgery, and after 6 and 12 weeks. The bone level in the immediate proximity of the implant was determined by radiovisiography (RVG). Results: The bone level after 12 weeks in Groups B and C was significantly higher than after 6 weeks. The bone level in the study Group B was significantly higher than in Group A. The study showed that the higher the levels of 25-hydroxycholecalciferol were observed on the day of surgery, the higher was the level of bone surrounding the implant after 6 and 12 after surgery. Conclusion: The correct level of 25-hydroxycholecalciferol on the day of surgery and vitamin D deficiency treatment significantly increase the bone level at the implant site in the process of radiologically assessed osseointegration.

Download Full-text

Prevention of Hepatitis B Infection in Newborns Through Mass Screening and Delayed Vaccination of All Infants of Mothers With Hepatitis B Surface Antigen

PEDIATRICS ◽

10.1542/peds.83.6.1041 ◽

1989 ◽

Vol 83 (6) ◽

pp. 1041-1048

Author(s):

Solko W. Schalm ◽

J. Adriaan Mazel ◽

Gijsbert C. de Gast ◽

Rudolf A. Heijtink ◽

Meindert J. Botman ◽

...

Keyword(s):

Hepatitis B ◽

Pregnant Women ◽

Rural Area ◽

Surface Antigen ◽

Hepatitis B Surface Antigen ◽

Large City ◽

Hepatitis B Infection ◽

Active Vaccination ◽

Group A ◽

Group B

Beginning in 1982 all pregnant women undergoing prenatal routine blood analysis in three large city hospitals and one large rural area were tested for hepatitis B surface antigen (HBsAg). Infants of all HBsAg-positive mothers received hepatitis B immunoglobulin (HBIg), 0.5 mL/kg of body weight within two hours of birth and, after randomization, 10 µg of hepatitis B vaccine either at 0, 1, 2, and 11 months of age (schedule A) or at 3, 4, 5, and 11 months of age (schedule B). A second injection of HBIg (1 mL) was given to infants on schedule B at 3 months of age. Blood samples were obtained at 3, 6, 11, 12, 24, and 36 months. In a two-year period, 28,412 pregnant women were tested for HBsAg; screening efficiency varied between 85% and 98%. The overall prevalence of HBsAg was 0.8%, with a marked variation between urban centers (2.2%) and the rural area (0.3%). Vaccinations were received by 180 of 193 infants of HBsAg-positive mothers (90 on schedule A and 90 on schedule B). Concentrations of hepatitis B surface antibody less than 10 IU/L were observed in nine instances in five children from group A and in seven instances in six children from group B. Four hepatitis B viral infections (two HBsAg carriers, two who underwent antihepatitis B core seroconversions) were recorded in group A v one infection (antihepatitis B core seroconversion) in group B. The protective efficacy of the program (screening plus passive immunization and delayed vaccination) was 94%. The estimated cost of preventing one case of hepatitis B infection in neonates was $3,000 (US currency). It is concluded that screening all pregnant women for HBsAg can be introduced effectively at reasonable costs in a country with a low prevalence of HBsAg and a high proportion of home deliveries. Delayed active vaccination starting at 3 months of age may be an effective and, for reasons of high compliance and low cost, attractive alternative to early active vaccination.

Download Full-text

Time out: should vitamin D dosing be based on patient's body mass index (BMI): a prospective controlled study

Journal of Nutritional Science ◽

10.1017/jns.2021.100 ◽

2021 ◽

Vol 10 ◽

Author(s):

Mir Sadat-Ali ◽

Khalid W. AlTabash ◽

Haifa A. Al-Turki ◽

Sulaiman A. AlMousa ◽

Hasan N. AlSayed

Keyword(s):

Vitamin D ◽

Vitamin D3 ◽

Standard Dose ◽

Demographic Data ◽

Controlled Study ◽

Daily Dose ◽

Calcium Phosphorus ◽

Group A ◽

Pre Treatment ◽

Group B

Abstract The recommended daily dose of vitamin D is 2000 IU was found to be insufficient in many patients. The objective of the present study is to find whether the daily dose of vitamin D should be based on BMI. Two hundred and thirty patients with an established vitamin D deficiency (serum level of 25 Hydroxy vitamin D3 (25OHD3) of ≤20 ng/ml) and patients with BMI ≥30 kg/m2 were included in the study. Demographic data, comorbidities and BMI were recorded. Pre-treatment and post-treatment serum 25OHD3, calcium, phosphorus and parathyroid hormone (PTH) were tested at 0-, 3- and 6-month periods. Patients were treated with a standard dose of 50 000 IU of vitamin D weekly and 600/1200 mg of calcium a day. Once their level of 25OHD3 reached ≥30 ng/ml, patients were randomised into two groups. Group A received a standard recommended maintenance dose of 2000 IU daily and Group B patients received 125 IU/kg/m2 of vitamin D3. The data were entered in the database and analysed. The mean age of Group A was 50⋅74 ± 7⋅64 years compared to 52⋅32 ± 7⋅21 years in Group B. In both groups, pre-treatment vitamin D level was ≤15 ng/ml and increased to 34⋅6 ± 2⋅6 and 33⋅7 ± 2⋅4 ng/ml at the end of 3 months treatment with a dose 50 000 IU of vitamin D3 and calcium 600/1200 mg once a day for group A and group B, respectively. At 6 months, patients in Group A 25OHD3 level was 22⋅8 ± 3⋅80 and in Group B was 34⋅0 ± 1⋅85 ng/ml (P < 0⋅001). This preliminary study suggests that obese patients need higher dosage of vitamin D than the recommended dose. It is prudent that the dosage should be based on the BMI to maintain normal levels for a healthy musculoskeletal system.

Download Full-text

Clinical efficacy of different dosage forms containing vitamin D: design and study outcomes of a randomized, comparative clinical trial

International Journal of Clinical Trials ◽

10.18203/2349-3259.ijct20203104 ◽

2020 ◽

Vol 7 (3) ◽

pp. 176

Author(s):

Nidhi Sapkal ◽

Gaurav Chhaya ◽

Milan Satya ◽

Dhara Shah

Keyword(s):

Vitamin D ◽

Clinical Efficacy ◽

Dosage Forms ◽

Oral Solution ◽

Blood Levels ◽

Open Label ◽

Soft Gelatin Capsules ◽

25 Hydroxy Vitamin D ◽

Group A ◽

Group B

Background: Different dosage forms of vitamin D like tablets, soft gelatin capsules, oral granules, powders, solutions and thin films are available. The objective of the present study was to evaluate and compare the clinical efficacy of three different dosage forms of vitamin D3 namely, orally disintegrating strips, oral granules and oral solution.Methods: An open label, single centre, prospective, randomized, parallel group, comparative study was conducted for a period of 4 months. The study participants were divided into three groups (A, B, C) and received the respective treatments (orally disintegrating strips, n=20; granules, n=20; oral nano solution, n=10) for the study period. The estimation of blood levels of 25-hydroxy vitamin D [25(OH)D3] in all the subjects at day 0, 60 and 120 was carried out.Results: The normalization level of 25(OH)D3 achieved by the subjects in group A, group B and group C was 100%, 83.3% and 90% respectively after 90 days. Comparison of 25(OH)D3 level in all three groups showed significant increase at day 60. The levels were maintained at day 90 and 120 even after drastic reduction in dosage in Group A and group C. On day 120, the dose reduction was in the order of group A>group C>group B.Conclusions: All the three formulations showed increase in the level of 25(OH)D3. It can be concluded that oral disintegrating strips of 25(OH)D3 are clinically more efficient than other conventional dosage forms.

Download Full-text

Fetal and Maternal Outcome Asymptomatic vs. Symptomatic Covid Positive Pregnant Women

10.53350/pjmhs2115103423 ◽

2021 ◽

Vol 15 (10) ◽

pp. 3423-3425

Author(s):

Amna Najam ◽

Samreen Fakeer Muhammad ◽

Samia Saifullah ◽

Maryam Shoaib ◽

Maria Anwar

Keyword(s):

Birth Weight ◽

Low Birth Weight ◽

Cesarean Section ◽

Pregnant Women ◽

Apgar Score ◽

Adverse Outcomes ◽

Maternal Outcomes ◽

Group A ◽

Nicu Admission ◽

Group B

Objective: The aim of this study is to compare the fetal and maternal outcomes in between asymptomatic and symptomatic COVID positive pregnant women. Study Design: Retrospective cohort study Place and Duration: The study was conducted at Gynae and Obs department of Sandeman Provincial Hospital, Quetta for duration of six months from November 2020 to April 2021. Methods: One hundred and ten pregnant women with ages 18-45 years had corona virus disease were presented. Informed written consent was taken from all patients for detailed demographics. COVID -19 was diagnosed by PCR. 55 patients had symptoms of coronavirus were included in group A and 55 patients did not show symptoms were included in group B. Frequency of pre-eclampsia, gestational diabetes mellitus and post-partum haemorrhage were calculated. Maternal adverse outcomes (cesarean section, instrumental delivery, induction of labor and prolong labor, hypertensive disorder) were calculated among both groups. Fetal outcomes perinatal mortality, Low birth weight, Low Apgar score and NICU admission were observed. SPSS 20.0 version was used to analyze all data. Results: Mean age of the patients in group A was 28.47±3.18 years with mean BMI 24.03±5.24 Kg/m2 and in group B mean age was 27.99±4.17 years with mean BMI 24.44±6.41 Kg/m2. Maternal outcomes (cesarean section, instrumental delivery, induction of labor and prolong labor,) in symptomatic group were significantly higher than that of asymptomatic group. Fetal outcomes, perinatal mortality in group A 9 (16.4%) and in group B was 5 (9.1%), low birth weight in group A was among 21 (38.2%) and in group B was 10 (18.2%), low apgar score in group A was 11 (20%) and in group B was 8 (14.4%), 15 (27.3%) in group A went to NICU admission and 3 (5.5%) patient in group II admitted to NICU. Conclusion: In this study we concluded that adverse outcomes among symptomatic COVID pregnant women were higher than that of asymptomatic coronavirus pregnant women in terms maternal and perinatal outcomes. Keywords: Pregnant women, Coronavirus, Symptomatic, Asymptomatic, Adverse Outcomes

Download Full-text

P–662 Study on D-vitamin, AMH and insulin interrelation in Polycystic Ovary Syndrome (PCOS) patients

Human Reproduction ◽

10.1093/humrep/deab130.661 ◽

2021 ◽

Vol 36 (Supplement_1) ◽

Author(s):

A Coc. Lizarraga ◽

S Lindenberg ◽

G Juu. Almind ◽

F Lindenberg

Keyword(s):

Insulin Resistance ◽

Vitamin D ◽

Vitamin D Deficiency ◽

Serum Vitamin ◽

Serum Vitamin D ◽

Vitamin D Levels ◽

Group A ◽

D Values ◽

Group B

Abstract Study question Is vitamin D deficiency more prevalent in PCOS patients? Is there a link between vitamin D levels and metabolic status in PCOS subjects? Summary answer An inverse relationship between vitamin D levels and metabolic status was demonstrated and it is thought to be responsible of its pathogenesis. What is known already PCOS is a multifactorial condition, characterised by failure in oogenesis and anovulation. Obesity is a common condition linked to its clinical features and studies have reported inverse associations between BMI and severity of the condition. Furthermore, 67–85% of PCOS patients have vitamin D deficiency. Low levels of vitamin D have been found to be closely related to insulin resistance, obesity, or hyperandrogenism and there is a significant association between serum vitamin D levels and reproductive function. Other factors such as AMH have also been described as possibly involved in the pathophysiology. Study design, size, duration We performed a retrospective, analytical and observational study in the Copenhagen Fertility Center. Patients referred with cycle abnormalities, hirsutism, and infertility were evaluated. A total of 778 women were enrolled consecutively from January 2019 to October 2020. Subjects who had major medical disorders were excluded. We selected those in which vitamin D was measured in the baseline analysis selecting a total of 396 patients. The further analysis has been carried out from 100 randomly selected patients. Participants/materials, setting, methods Blood samples were drawn after overnight fasting. They were all assayed in the same laboratory. Biochemical parameters were analyzed using descriptive statistics. Same parameters were studied after dividing into vitamin D deficiency group or optimal levels using a multiple t-test. Correlation between variables was determined. Graphpad Prism program version 8 was used to perform the calculations. The level of statistical significance was set at P-value < 0.05. Main results and the role of chance A total of 100 subjects fulfilling the inclusion criteria were selected randomly from 396 PCOS women. Serum vitamin D concentrations were highly variable ranging from 16 nmol/L to 175 nmol/L. The prevalence of vitamin D deficiency was 24% and 41% of the subjects were classified as vitamin D insufficient. Only 35% of our patients had optimal vitamin D values. We compared data between the group with optimal values of vitamin D (Group A) versus the group with insufficient/deficient vitamin D values (Group B). We found statistical difference between groups in PTH values, being notably higher in group B compared with group A. Despite no statistically significant difference was obtained, it is important to highlight that the mean of SHBG was lower in group B and the mean of androstenedione, AMH, FAI and HOMA-IR were much higher in this group as well. Following the HOMA-IR criteria, 55% of patients had insulin resistance. Specifically, 26% had moderate insulin resistance and 29% severe insulin resistance. Levels of vitamin D were negatively correlated with FAI, AMH and HOMA-IR and positively correlated with HDL-Cholesterol and SHBG. Statistically significant differences were evidenced in the correlation between vitamin D and FAI and SHBG. Limitations, reasons for caution This is a retrospective observational study on a consecutive admitted patient group with a lack of a control group. Another limitation is the small sample size. It is difficult to generalize with other degrees of severity. We didn’t assess seasonal variability or if they were taking any vitamin D supplementation. Wider implications of the findings: Properly randomized clinical trials are mandatory to achieve more conclusive results about the role of vitamin D. Available evidence is promising but not sufficient to draw final conclusions. The aim is to better understand the pathophysiology of the condition and the factors involved and to find new target treatments. Trial registration number 1

Download Full-text

Comparison of Maternal and Perinatal Outcome in Pregnant Women with Hypothyroidism Diagnosed before Conception with Hypothyroidism Diagnosed during Pregnancy

Journal of Universal College of Medical Sciences ◽

10.3126/jucms.v2i2.11170 ◽

2014 ◽

Vol 2 (2) ◽

pp. 21-27

Author(s):

P Basnet ◽

N Aggrawal ◽

V Suri ◽

P Dutta ◽

K Mukhopadhyay

Keyword(s):

Birth Weight ◽

Pregnant Women ◽

Thyroid Function ◽

Early Pregnancy ◽

Perinatal Outcome ◽

Fetal Outcome ◽

Endocrine Disorder ◽

Fetal Birth Weight ◽

Group A ◽

Group B

BACKGROUND: Thyroid disorder is one of commonest endocrine disorder in women and hence constitutes a common endocrine disorder complicating pregnancy. Diagnosing and treating hypothyroidism preconceptionally and during early pregnancy appears to be a useful strategy to improve maternal and fetal outcome. OBJECTIVE: To compare the maternal and perinatal outcome in pregnant women with hypothyroidism diagnosed preconceptionally with hypothyroidism diagnosed during pregnancy. METHODS: A prospective study. One hundred pregnant women with hypothyroidism at less than 20 weeks Period of Gestation (POG) were recruited for the study and grouped into two groups: Group A-hypothyroidism diagnosed and on treatment before conception, Group B-hypothyroidism diagnosed and started on treatment during pregnancy. Both groups were intensively monitored during pregnancy with serial Thyroid Function Test (TFT) and thyroxine replacement doses were adjusted accordingly. Various maternal, perinatal and fetal outcome measures were studied in both groups prospectively till delivery. RESULTS: The maternal and fetal complications were comparable in the two groups, however the fetal birth weight was significantly higher in Group A versus Group B (2.89±0.485kg vs. 2.70±0.453kg; p=0.039). All the new born babies had normal thyroid function. CONCLUSION: Hypothyroidism diagnosed preconceptionally or during early pregnancy and treated appropriately has beneficial effect on fetal birth weight, and hence the total pregnancy outcome. Screening for thyroid dysfunction should be judiciously performed in all high risk women prior to a planned conception or during their first antenatal visit. DOI: http://dx.doi.org/10.3126/jucms.v2i2.11170 Journal of Universal College of Medical Sciences (2014) Vol.2(2): 21-27

Download Full-text

Fragility Vertebral Compression Fractures in Postmenopausal Women: The Role of a Fracture Liaison Service Program

The American Surgeon ◽

10.1177/0003134820933254 ◽

2020 ◽

pp. 000313482093325

Author(s):

Avery Jackson ◽

Tarik Wasfie ◽

Caramarie Brock ◽

Stefanija Galovska ◽

Melany Smalley ◽

...

Keyword(s):

Vitamin D ◽

Postmenopausal Women ◽

Fragility Fractures ◽

Fracture Liaison Service ◽

Vertebral Compression Fractures ◽

Compression Fractures ◽

Vitamin D Levels ◽

Group A ◽

Group B ◽

Fracture Liaison

Background As the aging population increases in the United States, so has the prevalence of osteoporosis (10.2 million adults aged 50 years and older in 2010). Programs to manage the increased incidence of fragility fractures in such patients particularly the postmenopausal women are the priority. Programs such as the Fracture Liaison Service (FLS) might be the answer. Methods Data of 256 postmenopausal women with vertebral compression fractures treated with vertebroplasty between 2012 and 2017 were divided into 2 groups. Group A were patients seen between 2012 and 2014 before the establishment of the FLS program at the clinic. Group B were patients seen between 2015 and 2017 who presented to the FLS program in our clinic. Data collected included demographics, refracture rates, dual-energy X-ray absorptiometry (DEXA) scan T-scores, fracture risk score (FRAX), serum calcium and vitamin D levels, and comorbid conditions. Results There were 103 female patients with a mean age of 79.75 years (standard deviation [SD] ± 10.86) in group A, while group B had 153 patients with a mean age of 75.66 years (SD ± 10.78). There was no significant difference in the DEXA scan T-scores, FRAX scores, and mean serum calcium and vitamin D levels; however, there was a significant reduction in the refracture rate for vertebral compression fractures ( P = .003). Conclusion FLS programs, when implemented, will have a beneficial effect in reducing refracture rates of postmenopausal women with osteoporotic fragility fractures.

Download Full-text